Anke Biotechnology's wholly-owned subsidiary, Shanghai Suohao Yiming Pharmaceutical, has obtained a Certificate of Suitability to the European Pharmacopoeia for the active pharmaceutical ingredient octreotide, issued by the European Directorate for the Quality of Medicines. The certificate takes effect on July 31, 2026, and marks the third CEP certificate for peptide APIs obtained by Suohao Yiming. It will provide market access qualification for the company's octreotide API to enter the EU market and positively impact the overseas expansion of its peptide API business. In the first quarter of 2026, Anke Biotechnology achieved revenue of 542 million yuan and net profit attributable to the parent company of 168 million yuan.
Anhui Anke BioTech GroupEU CEP certificate grants market access for octreotide API, boosting overseas expansion.